Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Samsung Epis Holdings Co., Ltd.
Samsung Epis Holdings makes and sells biologic medicines, mainly biosimilars, that treat autoimmune, cancer, eye, blood, and bone diseases around the world.
Samsung Epis Holdings is a biopharmaceutical company that makes biologic medicines — drugs grown in living cells rather than mixed from chemicals — and sells them in markets around the world. Its signature business is biosimilars: near-copies of expensive original biologic drugs whose patents have expired or are expiring. A biosimilar is not an exact generic clone the way a pill can be; it is a highly similar version of a complex protein drug, and it must be proven safe and effective and win regulatory approval before it can be sold.
The company's products target serious diseases across several areas: autoimmune conditions, cancer, eye disorders, blood diseases, and bone disease. These are treatments patients often receive for months or years, frequently by infusion or injection, so they are high-value medicines sold through hospitals, clinics, and specialist doctors rather than drugstores. Customers are doctors and health systems, and increasingly insurers and governments that want cheaper alternatives to the original brands. The pitch is straightforward: a similar medicine at a lower price, which frees up money for health systems that are squeezed by costly biologics. Biosimilars are a brutal, capital-hungry business. You need large manufacturing plants, years of clinical testing, and regulatory approvals in each country, and you typically launch into price wars against the original maker and other copycats. The winners are usually the manufacturers with scale, reliable quality, and a deep pipeline of products coming off patent. Samsung Epis Holdings sits inside the wider Samsung corporate world, which gives it manufacturing muscle and global reach, but it also faces established rivals in the space such as Amgen and Pfizer, plus other biosimilar specialists.
The big question for investors is whether the company can keep converting its pipeline into approved products and win share in lucrative markets like the United States and Europe, where pricing pressure is intense but volumes are huge. It is a bet on patent cliffs — the steady stream of blockbuster biologic drugs losing protection — and on the company's ability to be a low-cost, high-quality producer. It is not a business that grows smoothly; it is a series of product launches, approvals, and price negotiations.
Saved answer · last researched 12 Nov 2026